Detail akcie AbbVie Inc online

Business Summary: AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
Financial Summary: BRIEF: For the three months ended 31 March 2026, AbbVie Inc revenues increased 12% to $15B. Net income applicable to common stockholders decreased 46% to $685M. Revenues reflect United States segment increase of 10% to $10.37B, All Other Countries segment increase of 37% to $1.03B, International segment increase of 4% to $3.33B. Dividend per share increased from $1.64 to $1.73.